28(40%) were males, with a mean age of 49±10 yrs. 80% were African Americans. 32% were asymptomatic, while

40% had gastrointestinal symptoms. The prominent liver test abnormality was an elevated GSK-3 beta pathway alkaline phosphatase (AP) level (375±383 IU/L). Angiotensin-converting enzyme (ACE) levels were elevated only in 49% of tested patients (n=53). Of 55 patients who had a liver biopsy, 30(55%) had no fibrosis, 14(25%) had stage 1-2, and 9(16%) had stage 3-4. 13 patients (11 treated) had paired liver biopsies over a 59±38 mos interval; 6(46%, 1 untreated) showed no change, 6(46%, 1 untreated) showed improved fibrosis, while 2(15%) showed worse fibrosis at follow-up. 52(74%) patients were treated for sarcoidosis, 31(60%) with corticosteroids, 19(37%) with ursodeoxycholic acid, 18(35%) with other immunotherapy agents. Demographic and baseline laboratory data and the follow-up periods were similar between the treated (Tx) and the untreated (No Tx) groups, except for a higher albumin in the No Tx group (4.2±0.4 vs 3.9±0.5 g/dL, p=0.02) and a lower AP in the No Tx group (224±207 vs 428±416 IU/L, p=0.05). Comparison of baseline and follow-up laboratory data for learn more each group are shown in the table. 6% of patients in each group either died or required OLT. Conclusions: Liver chemistry tests may improve in hepatic sarcoidosis with or without therapy, although untreated patients had lower

AP at baseline in this study. Transplant-free survival is similar in treated and untreated patients. Disclosures: K. Gautham Reddy – Advisory Committees or Review Panels: AASLD Transplant Hepatology Pilot Steering Committee, ACG Training Committee, Program Director’s Caucus Steering Committee; Grant/Research Support: Intercept, Ocera, Merck, Lumena Nancy Reau – Advisory Committees or Review Panels: Kadmon, Jannsen, Vertex, Idenix, AbbVie, Jannsen; Grant/Research Support: Vertex, Gilead, Genentech, AbbVie, BMS, Jannsen, BI Donald M. Jensen – Grant/Research Support: Abbvie, Boehringer, BMS, Genen-tech/Roche, Janssen Helen S. Te – Advisory Committees

or Review Panels: Gilead Sciences, Jansenn Pharmaceuticals; Grant/Research this website Support: Abbvie, BMS The following people have nothing to disclose: Nicole M. Welch, Andrew Aronsohn Background: Recent findings from the prospective UK-PBC patient cohort have shown that non-response to ursodeoxycholic acid (UDCA) therapy is associated with increased risk of death or need for transplant in PBC. Younger age at presentation and male gender were associated with increased risk of UDCA non-response. Although the implication is that age at presentation and gender are therefore risk factors for death and transplantation in PBC, the link as yet, has only been an indirect one. Here we set out to utilise the historic Newcastle cohort to directly explore the impact of age at presentation and gender on outcomes in PBC.